1983 Volume 24 Issue 6 Pages 620-626
The efficacy of anti-HB immune globulin and HB vaccine for the prevention of vertical transmission of HB virus to babies born to HB carrier mothers has been investigated.
Thirty eitht babies bom to HBe antigen-positive mothers received 150mg of HBIG·F (ab')2 intravenously within two hours after delivery and serum anti-HBs antibody titer (PHA) was kept higher than 222 by subcutaneous injection of HBIG thereafter. The interval between each HBIG injection was three months in most cases. The administration of HB vaccine was started at three months after delivery. Three injections of HB vaccine were given to the babies at one month interval. It has been disclosed that all babies who were injected HBIG remained HBsAg-negative except for two cases who became HBs-Ag-positive shortly after birth.
About fifty percent of children became actively immunized after three dosis of HB vaccine and at present, 78.3% of the babies have obtained active immunization with mean injection of 3.4 dosis of HB vaccine.
No side effect has been observed by the administration of either HBIG or HB vaccine.
